Neomycin
This aminoglycoside antibiotic is used topically on the skin to prevent infection in minor cuts, burns, and wounds, and can also be taken orally to reduce bacteria in the intestines before surgery. It works by stopping bacteria from making the proteins they need to survive.
Молекулярная масса
614,6000 g/mol
LogP
-9,00
TPSA
353,00 Ų
Правило пяти Липинского
Не соответствует
Терапевтические области
Механизм действия
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
SMILES
C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
InChI
InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
Molecular Formula
C23H46N6O13
HBD / HBA
13 / 19
Вращаемые Связи
9
Тяжёлые Атомы
42
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
This aminoglycoside antibiotic is used topically on the skin to prevent infection in minor cuts, burns, and wounds, and can also be taken orally to reduce bacteria in the intestines before surgery. It works by stopping bacteria from making the proteins they need to survive.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Neomycin is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989751. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 8378. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="neomycin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/neomycin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/neomycin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/neomycin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="neomycin"></drugfyi-drug>